Alik Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.93 M
About Alik Pharmaceutical
Alik Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 March 2014 and has a history of Ten years and ten months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹3.93 M.
Mukesh Tomar, Vineet Srivastava, and Manoj Devi serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U51397DL2014PTC266845
- Company No.
266845
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2014
- Date of AGM
01 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Alik Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Tomar  | Director | 24-Mar-2014 | Current |
| Vineet Srivastava | Director | 24-Mar-2014 | Current |
| Manoj Devi | Director | 08-Apr-2022 | Current |
Financial Performance of Alik Pharmaceutical.
Alik Pharmaceutical Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Alik Pharmaceutical?
In 2017, Alik Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ginji Export Private LimitedMukesh Tomar and Vineet Srivastava are mutual person
Charges (Loans)
₹3.93 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.39 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 May 2020 | State Bank Of India | ₹3.93 M | Open |
How Many Employees Work at Alik Pharmaceutical?
Alik Pharmaceutical has a workforce of 9 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alik Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alik Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
